Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10056838 | 0.82 | GABRR1 (0.44) | BCAT2CYP2C19CYP2D6GABRR1 | |
| SCHEMBL1331722 | 0.82 | GABRR1 (0.44) | BCAT2CYP2C19CYP2D6GABRR1 | |
| SCHEMBL10055164 | 0.82 | GABRR1 (0.44) | BCAT2CYP2C19CYP2D6GABRR1 | |
| SCHEMBL16157279 | 0.79 | BCAT2 (0.39) | BCAT2CYP2C19CYP2D6MEN1KMT2A | |
| SCHEMBL14704194 | 0.76 | BCAT2 (0.37) | BCAT2CYP2C19CYP2D6MEN1KMT2A | |
| SCHEMBL10056281 | 0.74 | CA14 (0.39) | BCAT2CYP2C19CYP2D6MEN1KMT2A | |
| SCHEMBL10055155 | 0.74 | CA14 (0.39) | BCAT2CYP2C19CYP2D6MEN1KMT2A | |
| SCHEMBL15481501 | 0.74 | CA14 (0.39) | BCAT2CYP2C19CYP2D6MEN1KMT2A | |
| SCHEMBL23863 | 0.74 | — | — | |
| SCHEMBL12521641 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6369098-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-.GAMMA. (PPAR.GAMMA.) AND/OR PPAR.ALPHA TREATMENT OF ENDOCRINE, SKIN, CARDIOVASCULAR, IMMUNOLOGICAL, NEUROLOGICAL, NEUROPSYCHIATRIC, NEOPLASTIC AND CHRONIC VIRAL DISEASES OF VARIOUS ORGANS | BETHESDA PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | claimed |
| WO-2001025226-A1 | DITHIOLANE DERIVATIVES | BETHESDA PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | claimed |
| US-20190077774-A1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS | HOPE CITY (US) | 2019-03-14 | — | — | US | disclosed |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | GOETZE LEOPOLD F | 2007-10-04 | — | — | US | disclosed |
| EP-1765320-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | Pfizer Products Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006034485-A2 | TREATMENT FOR AGE-RELATED COGNITIVE DECLINE AND OTHER CONDITIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005115369-A2 | USE OF PPAR AGONISTS TO TREAT RUMINANTS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20040106135-A1 | Identifying peroxisome proliferator activated receptor (PPAR) modulator for use in treatment and prevention of hyperlipidemia and liver disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004024939-A2 | LIGANDS FOR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR, AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1399426-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | Active Pass Pharmaceuticals, Inc. (CA) | 2004-03-24 | — | — | EP | disclosed |
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2002100836-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002052039-A2 | METHODS FOR SELECTING AND PRODUCING PHARMACEUTICAL COMPOUNDS USING A LIBRARY RESPONSIVE TO TRANSCRIPTION FACTORS | GENEKA BIOTECHNOLOGY INC. (CA) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | BCAT2 1743/4885CYP2C19 3665/4885CYP2D6 3822/4885 |
| US-20070232647-A1 | Use of Ppar Agonists to Treat Ruminants | PPARG, PPARD, PPARA | BCAT2 1281/4885CYP2C19 2588/4885CYP2D6 2123/4885 |
| US-20190077774-A1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS | PPARG, PPARA, PPARD | BCAT2 979/4885CYP2C19 1678/4885CYP2D6 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.